Browsing by Author "Akkaya C."

Now showing 1 - 6 of 6
  • No Thumbnail Available
    Item
    Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: An international, multicenter study
    (Lippincott Williams and Wilkins, 2009) Alptekin K.; Hafez J.; Brook S.; Akkaya C.; Tzebelikos E.; Ucok A.; Tallawy H.E.; Danaci A.-E.; Lowe W.; Karayal O.N.
    To compare the effectiveness of a switch from haloperidol (N=99), olanzapine (N=82), or risperidone (N=104) to 12 weeks of treatment with 80-160 mg/day ziprasidone in patients with stable schizophrenia or schizoaffective disorder. Stable outpatients with persistent symptoms or troublesome side effects were switched using one of three 1-week taper/switch strategies as determined by the investigator. Efficacy was assessed using the Brief Psychiatric Rating Scale score, Clinical Global Impression, Positive and Negative Symptom Scale, Montgomery-Åsberg Depression Rating Scale, and the Global Assessment of Functioning Scale, and tolerability by using standard measures of weight change, extrapyramidal symptoms, and laboratory findings. Suboptimal efficacy was the primary reason for switching. The preferred switch strategy was immediate discontinuation, and the preferred dosing regimen was 120 mg/day. Completer rates were 68, 60, and 86% in the haloperidol, risperidone, and olanzapine pre-switch groups, respectively. At week 12, a switch to ziprasidone resulted in statistically significant improvement from baseline on the Brief Psychiatric Rating Scale score, Clinical Global Impression- Improvement, Positive and Negative Symptom Scale, and Global Assessment of Functioning scales, reduction in extrapyramidal symptoms and a neutral impact on metabolic parameters. Switch from olanzapine and risperidone resulted in weight reduction and from haloperidol in some weight increase. In conclusion, oral ziprasidone of 80-160 mg/day with food was a clinically valuable treatment option for stable patients with schizophrenia or schizoaffective disorder experiencing suboptimal efficacy or poor tolerability with haloperidol, olanzapine, or risperidone. © 2009 Lippincott Williams & Wilkins, Inc.
  • No Thumbnail Available
    Item
    Association of social anxiety with stigmatisation and low self-esteem in remitted bipolar patients
    (Cambridge University Press, 2011) Aydemir O.; Akkaya C.
    Background: In remitted bipolar disorder, it is aimed to show the association between social anxiety, self-esteem and stigmatisation. Methods: From two university clinics, a sample of 150 remitted bipolar patients was included in this study. Patients were assessed with Liebowitz Social Anxiety Scale, Rosenberg Self-Esteem Scale and sense of stigmatisation subscale of Bipolar Disorder Functioning Questionnaire (Stigma) and were rated with Hamilton Depression Rating Scale and Young Mania Rating Scale for mood symptoms. Confirmatory path analysis was performed. Results: The mean age of the patients was 39.5, and 52.7% (n = 79) were female. Ninety per cent (n = 135) of the patients had bipolar I disorder. The mean duration of the illness was 13.4 years and the mean number of episodes was 7.8. The model was subjected to confirmatory path analysis and the goodness-of-fit index was calculated to be 0.909, the confirmatory fit index was found to be 0.902 and the root mean square error of approximation was 0.097. Self-esteem was negatively associated with stigmatisation (r = -0.746). Social anxiety was positively associated with self-esteem (r = 0.494). Social anxiety was negatively associated with stigmatisation (r = -0.381). Conclusions: In remitted bipolar patients, social anxiety is very high and this social anxiety seems to be caused by self-stigmatisation and low self-esteem. © 2011 John Wiley & Sons A/S.
  • No Thumbnail Available
    Item
    Reliability and validity of turkish version of biological rhythms interview of assessment in neuropsychiatry
    (2012) Aydemir Ö.; Akkaya C.; Altinbaş K.; Kora K.; SüCüllüoglu Dikici D.; Akdeniz F.; Kalayci F.; Oral E.T.; Vahip S.
    Objective: In this study, it is aimed to perform the validity and reliability of the Turkish version of Biological Rhythms Interview of Assessment in Neuropsychiatry. Methods: The study was performed with 79 bipolar type-I disorder, 26 bipolar type-II disorder and 42 major depressive disorder patients attending to mood disorder clinics of three university hospitals and one state training hospital as well as 116 university students consisting healthy control subjects. The mean duration of the illness was 15.1 years for the bipolar groups and 9,3 years for the depressive group. For concurrent validity, Pittsburgh Sleep Quality Index was used. In the statistical analyzes, internal consistency coefficient, item-total score correlations, exploratory and confirmatory factor analyzes, correlation with the other scale and ROC curve were calculated. Results: The forward and back translation of the Biological Rhythms Interview of Assessment in Neuropsychiatry was performed, and linguistic equivalence was obtained with the scale prepared. In internal consistency, the Cronbach's alpha coefficient was found to be 0.899 and item-total correlation coefficients were between 0.239 and 0.747. In the exploratory factor analysis, a total of three factors representing 56.5% of the total variance were obtained and the themes of the factors were daily activities, sleep and eating habits and interpersonal relations. In the confirmatory factor analysis, confirmatory fit index was 0.932 and root mean square of approximation was 0.065. The correlation between Biological Rhythms Interview of Assessment in Neuropsychiatry and Pittsburgh Sleep Quality Index was found to be r=0.238. In the sensitivity and specificity analysis, the area under the ROC curve was 0.876. The scale discriminated mood disorder groups from the healthy control group. Conclusion: It is shown that the Turkish version of Biological Rhythms Interview of Assessment in Neuropsychiatry which is used in the assessment of circadian rhythm and functionality is reliable and valid.
  • No Thumbnail Available
    Item
    Effect of facial emotion recognition on subjective psychosocial functioning in bipolar patients
    (2013) Aydemir O.; Akkaya C.; Uykur B.; Erol A.
    [No abstract available]
  • No Thumbnail Available
    Item
    The Turkish adaptation, validity, and reliability of the internal states scale; [İçsel Durum Ölçeği’nin Türkçeye Uyarlaması, Geçerlik ve Güvenirlik Çalışması]
    (Turkish Neuropsychiatric Society, 2016) Maçkali Z.; Akkaya C.; Aydemir Ö.
    Introduction: The Internal State Scale (ISS) was developed to simultaneously assess manic and depressive symptoms in bipolar disorder. In the present study, the validity and reliability of the Turkish version of ISS (ISS-TR) were examined. The present study aimed to present the psychometric properties of this scale. Methods: The sample consisted of 200 outpatients with bipolar disorder and 49 healthy controls. Participants completed the Turkish Internal State Scale (ISS-TR), the Brief Psychiatric Rating Scale (BPRS), the Hamilton Depression Rating Scale (HDRS), and the Young Mania Rating Scale (YMRS). Results: Reliability analyses revealed that the Cronbach alfa coefficient of ISS was 0.88 for the whole sample. Item-total correlations ranged from 0.15 to 0.78. Two factors emerged as a result of factor analysis: “mania” and “depression-well-being.” Test–retest correlations were determined for the mania subscale as r=0.654, p<0.01 and for the depression-well-being subscale as r=0.356, p<0.01. The correlations between BPRS and both subscales were quite high. The correlation between HDRS and the depression-well-being subscale was higher (r=0.475) than that between HDRS and the mania subscale, whereas the correlation between YMRS and the mania subscale was higher (r=0.818) than that between YMRS and the depression-well-being subscale. It was seen that ISS could discriminate between the clinical and healthy control samples. In addition, it was observed that the mania subscale predicted a manic period more strongly, while the depression- well-being subscale predicted a depressive period better. Conclusion: ISS is a valid and reliable scale that can be used to simultaneously assess manic and depressive symptoms. It is thought that ISS will be useful in the recognition of prodromal symptoms and in the process of maintenance treatment. © 2016 by Turkish Association of Neuropsychiatry.
  • No Thumbnail Available
    Item
    Reliability and validity study of the Turkish version of Hypomania Checklist-32-Revised
    (Turkish Association of Nervous and Mental Health, 2017) Vahip S.; Aydemir Ö.; Akkaya C.; Altinbaş K.; Kora K.; Sücüllüoğlu Dikici D.; Akdeniz F.; Kalayci F.; Oral E.T.; Vahip I.; Alkan M.; Angst J.
    Objective: In this study, we aimed to evaluate the reliability and validity of the Turkish version of Hypomania Checklist-32-Revised. Method: The study was carried out with 80 patients diagnosed with bipolar I disorder, 26 patients diagnosed with bipolar II disorder and 42 patients diagnosed with major depressive disorder attending the out- and in-patient psychiatry departments of three university hospitals and one training hospital and 116 healthy volunteers consisting of university students. Mean duration of illness was 15.1 years for the bipolar disorder group and 9.3 years for the major depressive disorder group. For concurrent validity, the Mood Disorder Questionnaire was used. In the statistical analysis, internal consistency coefficient, item-total score correlation coefficients, exploratory factor analysis, correlation with concurrent scale and ROC curve were calculated. Results: Translation into Turkish and back-translation into English of Hypomania Checklist-32-Revised were performed and thus the semantic harmony of the scale was obtained. In the internal consistency, Cronbach alpha coefficient was 0.914 and item-total score correlations were between 0.235-0.743. Unlike the rest, the coefficient of item #23 was found as 0.110. In factor analysis, six factors were obtained; however, a two-factor solution representing 44.5% of the total variance was accepted whereas the first factor represents overactivity and being expansive, where the second factor represents impulsivity and risky behaviors. Correlation of Hypomania Checklist-32-R with Mood Disorder Questionnaire was r=0.379. In the ROC analysis, the cutoffpoint of the scale was calculated as 14 with a sensitivity of 71.0 and specificity of 69.8. The scale discriminates well between the bipolar group, depressive and control groups. Conclusion: Hypomania Checklist-32-Revised developed for screening hypomania is reliable and valid in Turkish after exclusion of item #23.